OneMedNet (NASDAQ:ONMD) announced that it has entered into a significant iRWD customer data licensing agreement, partnering with an undisclosed U.S.-based global leader in clinical trial design and software with products and services utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companies.
OneMedNet will utilize its proprietary iRWD platform to securely search, de-identify, and curate current, regulatory-grade clinical data for the new customer, including its worldwide subsidiaries and affiliates, under a referral licensing model that provides a robust funnel of business opportunities.
In a statement, Aaron Green, president and CEO of OneMedNet, said that the partnership aligns perfectly with OneMedNet’s market expansion strategy and significantly extends its commercial reach within the global science industry. “Our new partner’s recognized expertise in clinical trial design and implementation, combined with our innovative RWD platform, creates a powerful synergy that should help accelerate the development of innovative new medical therapies and technologies targeting some of the world’s greatest health challenges.”
